Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Hims Claws Back After Its Lilly-Rivaling Obesity Plan Faces An Unexpected Hitch
In This Article:
Hims stock clawed higher Wednesday though analysts laid out low expectations for Him & Hers' branded tirzepatide.
Terms and Privacy Policy